Market News
Elekta has won a major tender where the Health Department of the People’s Liberation Army (PLA) is expanding its capacity to treat cancer.
Cancer is one of the leading causes of death in China, according to the Earth Policy Institute, and with an aging population, the number of cancer patients is forecasted to grow significantly in the coming years. The PLA, which manages the military hospitals, is addressing the challenge presented by the high incidence and mortality of cancer by awarding a public tender to Elekta for the purchase of cancer management solutions.
Elekta will deliver a comprehensive range of clinical solutions, including Leksell Gamma Knife® as well as linear accelerators and associated software. The total value of the contract amounts to some USD 35 million, making it Elekta’s largest deal ever in China. The order will be booked when all conditions in the tender have been finalized.
Gilbert Wai, Executive Vice President, Region Asia Pacific says: “By partnering with Elekta, the PLA hospitals will help more cancer patients to receive the treatment they need in their battle with cancer. This deal is the latest in many with the PLA, demonstrating the great faith it has in Elekta and our products. It also strengthens Elekta’s number one position in the Chinese market.”
Elekta has been present in China since 1982 and is now the company’s third largest market. “Our commitment to improving access to high quality cancer treatment and management goes beyond selling products,” says Wai. “As a comprehensive solutions partner in China, Elekta helps with clinical implementation as well as education and training services.”
based on a Press Release
Elekta wins USD 35 million tender in China with its army
Thursday, 30 August 2012Elekta has won a major tender where the Health Department of the People’s Liberation Army (PLA) is expanding its capacity to treat cancer.
Cancer is one of the leading causes of death in China, according to the Earth Policy Institute, and with an aging population, the number of cancer patients is forecasted to grow significantly in the coming years. The PLA, which manages the military hospitals, is addressing the challenge presented by the high incidence and mortality of cancer by awarding a public tender to Elekta for the purchase of cancer management solutions.
Elekta will deliver a comprehensive range of clinical solutions, including Leksell Gamma Knife® as well as linear accelerators and associated software. The total value of the contract amounts to some USD 35 million, making it Elekta’s largest deal ever in China. The order will be booked when all conditions in the tender have been finalized.
Gilbert Wai, Executive Vice President, Region Asia Pacific says: “By partnering with Elekta, the PLA hospitals will help more cancer patients to receive the treatment they need in their battle with cancer. This deal is the latest in many with the PLA, demonstrating the great faith it has in Elekta and our products. It also strengthens Elekta’s number one position in the Chinese market.”
Elekta has been present in China since 1982 and is now the company’s third largest market. “Our commitment to improving access to high quality cancer treatment and management goes beyond selling products,” says Wai. “As a comprehensive solutions partner in China, Elekta helps with clinical implementation as well as education and training services.”
based on a Press Release